<![CDATA[Pressat Main Newswire]]> https://pressat.co.uk/ https://pressat.co.uk/media/site/logo.png https://pressat.co.uk/category/medical-pharmaceutical/ en-gb Copyright: (C) Pressat Pressat <![CDATA[ Hat-trick of awards for Marie and Jack Shapiro Prize winner! ]]> https://pressat.co.uk/releases/hat-trick-of-awards-for-marie-and-jack-shapiro-prize-winner-babafe7e491992eca0cc658f13288f4f https://pressat.co.uk/releases/hat-trick-of-awards-for-marie-and-jack-shapiro-prize-winner-babafe7e491992eca0cc658f13288f4f Friday 20 September, 2019

(Interview and photo opportunities are available)

September 2019
The British Tinnitus Association (BTA) has presented the prestigious industry award the Marie & Jack Shapiro Prize for the third year in succession to a team of clinicians and researchers led by Dr Eldré Beukes, a Research Fellow at Anglia Ruskin University (ARU).

The Shapiro Prize was presented at the BTA’s 26th Annual Conference in London, which was attended by audiologists, hearing professionals, researchers and BTA members. It was awarded for the paper “Effectiveness of Guided Internet-Based Cognitive Behavioral Therapy vs Face-to-Face Clinical Care for Treatment of Tinnitus: A Randomized Clinical Trial.”

The winning paper was chosen from a shortlist of 30, which is record number of eligible papers. The judging panel was formed of the BTA’s Professional Advisers’ Committee.

Psychological treatments such as Cognitive Behavioural Therapy are a proven intervention for reducing tinnitus distress. Beukes and her colleagues compared an internet-based Cognitive Behavioural Therapy (iCBT) intervention with face-to-face therapy for those experiencing tinnitus in the United Kingdom.

The judges said: “This study focused on cognitive behavioural therapy (CBT) for tinnitus, which is the most effective evidence-based treatment available, but only available to a minority of those who need it. More recently, internet-based CBT has been developed as a way of making this treatment available to more people. For the first time, Beukes and colleagues have shown in a randomized controlled trial that the internet-based treatment is as effective as face-to-face treatment, which may have major implications for providing effective treatment to many more people than presently available.”

Dr Eldre Beukes said: “It has been such a privilege being involved in this research and seeing the positive effects in helping those with tinnitus. We are so pleased and delighted to win this prize! It is a huge honour receiving it three years in a row. We want to thank the British Tinnitus Association for their support as it encouraged us to keep working at this important research aimed at improving the lives of those with tinnitus.”

She added: “This research has been such an exciting journey. The findings from this research opens up the possibility of an accessible, evidence-based intervention that is not currently available but can truly transform health care services. The findings indicate the clear potential of this intervention as an additional, effective, accessible tinnitus intervention for those struggling with the devastating effects of tinnitus. Receiving recognition for this work will greatly help to move this intervention forward.”

David Stockdale, Chief Executive of the British Tinnitus Association, said: “We are delighted to award Dr Beukes and her team the Marie & Jack Shapiro Prize for an unprecedented third time in a row. It indicates the real potential for iCBT as a tinnitus treatment which has obvious clinical benefits and the ability to improve the quality of life for people with tinnitus.

He adds: “The competition was tough this year as there were a record number of research papers in the running. The increased number of eligible papers year-on-year, and progress being made in tinnitus research is very encouraging to see, and offers hope as we drive progress towards a cure.”

The Marie & Jack Shapiro Prize is given each year at the BTA Conference to the piece of published research, by a UK based author, ‘most likely to result in improved treatment or public awareness of tinnitus,’ that was published in the last calendar year. The prize is named after the late Jack Shapiro, the founder of the British Tinnitus Association, and his wife Marie, who both played an important role in the establishment of the charity and in raising awareness of tinnitus.



Beukes EW, Baguley DM, Allen PM, Manchaiah V & Andersson G. (2018). Audiologist-Guided Internet-Based Cognitive Behaviour Therapy for Adults with Tinnitus in the United Kingdom: A Randomised Controlled Trial. Ear and Hearing. doi: 10.1097/AUD.0000000000000505

Editors Notes

The BTA is an independent charity which supports over one million people per year who experience tinnitus and advises medical professionals from across the world. It is the primary source of support and information for people with tinnitus in the UK.  The BTA needs to raise £975,000 each year to continue their UK wide support. Donations can be made via Tinnitus">www.tinnitus.org.uk/donateTinnitus">... is defined as the experience of sounds with no external source, most commonly ringing or buzzing, but sometimes experienced as whooshing, clicking or even music. Around one in eight adults experience tinnitus. Many people aren’t troubled by sounds they hear, but for around 10%, the condition has a significant impact on their quality of life, often linked to stress, anxiety or sometimes depression.

For more information

Nic Wray, Communications Manager


0114 250 9933

British Tinnitus Association
Ground Floor Unit 5 Acorn Business Park
Woodseats Close
Sheffield, S8 0TB

* For more information regarding media usage, ownership and rights please contact British Tinnitus Association.

Distributed by https://pressat.co.uk/ ]]>
20 Sep 2019 13:51:14 GMT
<![CDATA[ Haag-Streit UK announce the launch of the Ellex Eye Prime ]]> https://pressat.co.uk/releases/haag-streit-uk-announce-the-launch-of-the-ellex-eye-prime-8daf9ec178c6a0854462db077a78aec2 https://pressat.co.uk/releases/haag-streit-uk-announce-the-launch-of-the-ellex-eye-prime-8daf9ec178c6a0854462db077a78aec2 Thursday 19 September, 2019

Harlow, UK – 19th
September 2019 - Haag-Streit UK (HS-UK), the leading manufacturer and distributor of gold-standard optometry and ophthalmic equipment, is pleased to announce the launch of the Eye Prime diagnostic ultrasound system in the UK.

The Eye Prime is the next generation ultrasound solution from Ellex. It features the industry’s first and only Six-Ring Phased Annular Array Technology, delivering crisp, high-definition images and optimised focal point accuracy. This transforms the view of even the finest ocular structures, enabling the clinician to view, diagnose and treat more accurately and efficiently.

Eye Prime’s Six-Ring Phased Annular Array Technology transmits and receives ultrasound waves from six concentric transducers, which can be individually pulsed. This enables fine focus adjustment through a wide range of depths in 1mm increments, thereby enabling you to focus anywhere in the posterior segment and beyond.

The system delivers unparalleled levels of accuracy, flexibility and image quality. It refocuses the beam transmission at a wide range of depths, optimising the resolution at each pixel and extending the depth-of-field at each focal point, to deliver real-time, dynamic imaging.

Available modes include; 12 MHz & 18 MHz B-Scan and 35 MHz & 50 MHz UBM. Matched with Ellex’s proprietary Reflex Technology platform, the ultrasound system also represents the perfect partnership for the visualisation and treatment of symptomatic floaters. In 12 MHz mode, the large aperture, localised Time Gain Compensation (TGC) settings and deep focusing all combine to ensure that visualisation of subtle targets, such as vitreous membranes and opaque collagen clusters, are presented and defined in superior detail.

In 18 MHz mode you can tailor sensitivity and resolution across posterior pathology. Exquisite detail throughout the posterior segment reveals unsurpassed imaging of the retina, optic nerve and extraocular muscle. The option of 35 MHz and 50 MHz UBM modes enables the user to choose the resolution and penetration tailored for the application - and to view the entire anterior segment with less refraction.

Jacqui Kenyon, HS-UK Product Manager, said, “We are really excited to introduce the Ellex Eye Prime to the UK market. Ultrasonography plays a critical role in diagnostic ophthalmology, and the system’s breakthrough diagnostic ultrasound technology will be a huge benefit to any eyecare professional when evaluating pathology of the eye.”

For more information on Eye Prime, please visit https://hsuk.co/eyeprime, or email eyeprime@haag-streit-uk.com.

* For more information regarding media usage, ownership and rights please contact Haag-Streit UK.

Distributed by https://pressat.co.uk/ ]]>
19 Sep 2019 18:17:35 GMT
<![CDATA[ Haag-Streit Academy host a successful ‘Gold Standard’ Perimetry Course ]]> https://pressat.co.uk/releases/haag-streit-academy-host-a-successful-gold-standard-perimetry-course-8552939f5d40e10a9d6e94b76b43ed90 https://pressat.co.uk/releases/haag-streit-academy-host-a-successful-gold-standard-perimetry-course-8552939f5d40e10a9d6e94b76b43ed90 Friday 13 September, 2019

Harlow, UK – 13th September 2019 – Haag-Streit Academy hosted a successful ‘Gold Standard’ Perimetry Course on 10th September 2019. The education event, held at the Radisson Blu Hotel, Leeds, was extremely well-received, with excellent feedback from delegates.

The ‘Gold Standard’ Perimetry Course provided attendees with expert advice and a detailed overview of how to get the most out of their perimeter. The day included lectures and demonstrations delivered by perimetry specialist Prof. Fiona Rowe, Professor in Orthoptics & Health Services at the University of Liverpool.

Professor Rowe covered topics including; ‘System & test set-up’, ‘Static & kinetic examination’, ‘Test evaluation cluster’ and ‘Polar & trend analysis’. Other members of the faculty delivered a series of talks on the practicalities of using the Haag-Streit Octopus 900, the true successor to the Goldmann perimeter. They shared practical advice on how to use the instrument to achieve superior results in both kinetic and static perimetry.

In addition, delegates participated in hands-on sessions and test simulations facilitated by the Haag-Streit Academy team. The one day programme offered 6 CPD points.

Grant Duncan, HS-UK Clinical Training Manager, said, “We are very pleased with the success of the latest ‘Gold Standard’ Perimetry course. The practical workshops always receive excellent feedback and we chose to recruit a smaller group for this course, to ensure delegates could really benefit from the opportunity to gain hands-on experience with the state-of-the-art Octopus 900
perimetry system.”

Grant continued, “The smaller group size was a great success and as a result, we will certainly look to host a greater number of smaller, more focussed courses in the future.”

For further information on any of the future Haag-Streit Academy courses, please visit https://hsuk.co/eventbrite or email academy@haag-streit-uk.com

* For more information regarding media usage, ownership and rights please contact Haag-Streit UK.

Distributed by https://pressat.co.uk/ ]]>
13 Sep 2019 10:20:06 GMT
<![CDATA[ New Study Finds SkinVision Detects 95% of Skin Cancer ]]> https://pressat.co.uk/releases/new-study-finds-skinvision-detects-95-of-skin-cancer-470250379fb3c4519381e9a167d762d8 https://pressat.co.uk/releases/new-study-finds-skinvision-detects-95-of-skin-cancer-470250379fb3c4519381e9a167d762d8 Thursday 12 September, 2019

An international group of researchers working with Erasmus University Medical Center (Erasmus MC) in the Netherlands determined that SkinVision – the first CE-marked skin cancer application based on extensive clinical trials – has a sensitivity of 95.1% in detecting the most common forms of skin cancer. 

The research published in the Journal of the European Academy of Dermatology and Venereology (JEADV) evaluated the accuracy of the application for triaging skin lesions. The researchers found that the SkinVision algorithm has high sensitivity to detect skin cancer and can be a valuable tool for early skin cancer detection.

Early Recognition of Skin Cancer 

Skin cancer is a growing problem, with currently between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occurring each year globally. In fact, one in three cancers diagnosed is skin cancer. The good news is that 95% of skin cancers can be successfully treated if caught at an early stage.

As healthcare systems are adopting more innovative technology, there is increasing evidence that mobile health apps can help to save lives. SkinVision empowers individuals to take their skin health into their own hands by transforming their smartphone into a medical device for skin cancer risk assessment. So far, SkinVision has assisted in the finding of more than 35,000 skin cancer cases globally and managed to direct those people to a healthcare professional for further examination.

The service has the potential to triage those in need of treatment and could help to decrease both the average cost of treatment and the number of unnecessary doctor visits. The company has built up a customer portfolio of 1,200,000 users globally and a database of 3.5 million pictures of suspicious and benign skin spots.

‘The field of mHealth apps for the risk assessment of skin cancer is undergoing rapid evolution. It is clear from this and other recent studies based on clinical images that the application of machine learning in large image databases leads to a high sensitivity to distinguish between malignant and benign skin cancer cases,’ said Tiago M. C. D. Marques, postdoctoral researcher at Erasmus MC, and one of the study authors.

To evaluate the sensitivity of the algorithm, researchers used 285 histopathologically validated skin cancer cases from two previously published clinical studies and the smartphone application user database. The specificity was computed on a separate set from the user base, which contained 6,000 clinically-validated cases.

‘Providing the layperson with a highly sensitive, robust and easy-to-use method to check skin lesions for cancer has been the SkinVision research team’s goal for the past seven years,' said Andreea Udrea, a Ph.D. researcher at SkinVision, associate professor at University Politehnica of Bucharest and the lead author of the study. ‘I’m confident to say that SkinVision users benefit from the latest technological advancements that have been incorporated in a rigorous and clinically tested mHealth app.’

In terms of specificity, Erasmus MC is currently preparing a prospective study for further clinical validation, which will be performed at the Outpatient Dermatology Department during the coming months.


About SkinVision

SkinVision is headquartered in Amsterdam, the Netherlands. SkinVision was founded in 2012 and is an awareness and tracking solution that supports individuals with the early recognition of skin cancer. Research shows the app has a sensitivity of 95% and specificity of 78%, well above that of a GP, with a sensitivity of 60%. 

SkinVision has partnerships with leading health insurers, skin cancer clinics, and research universities in Australia, Germany, the Netherlands, Belgium, and New Zealand. SkinVision is a part of the NHS Innovation Accelerator in England and the Digital.Health London Accelerator working to spread innovation and save lives from skin cancer while relieving high pressure on health services. The SkinVision app is commercially available worldwide except for the United States and Canada.

For more information: SkinVision Press: Abigail Blackburn, abigail.blackburn@skinvision.com, M: +31 615 895 099


No media attached. Please contact SkinVision for more information.

Distributed by https://pressat.co.uk/ ]]>
12 Sep 2019 08:03:30 GMT
<![CDATA[ CBD HEALTH® from Canabidol® Releases New Variants of their First-of-a-Kind Supplements ]]> https://pressat.co.uk/releases/cbd-healthr-from-canabidolr-releases-new-variants-of-their-first-of-a-kind-supplements-3f9e34b1995c10a90ce7ab4f524a16eb https://pressat.co.uk/releases/cbd-healthr-from-canabidolr-releases-new-variants-of-their-first-of-a-kind-supplements-3f9e34b1995c10a90ce7ab4f524a16eb Monday 9 September, 2019

London, UK: Canabidol® the UK’s leading expert in consumer CBD products, is proud to announce the release of new line extensions to their innovative CBD HEALTH® range, with the addition of ‘Physio’ and ‘Relax’ to the ground-breaking oral suspension gel range.

To help meet the fast-growing demand from consumers looking to add CBD food supplements to their general health regime, CBD HEALTH® is the first range on the market to combine pure, 100% European Cannabis Sativa L. with complimentary ingredients, backed with approved EU Health Claims to help with a variety of daily health needs.

Canabidol® CEO, Tom Whettem, celebrated this break-through by commenting “We now are able to offer our customers and consumers the only ‘proven-to-be-good-for-you’ range of CBD products that support your health and general well-being. No other CBD product to date can, by law, make these claims or even suggest that their products are good for your health and well-being.”

Whettem added: “The substantial scientific data that backs up each of our formulations enables us to present products that have been certified and approved for use by the European Food Safety Authority. We are excited by the prospect of consumers being able to add CBD HEALTH® to their daily routines, which is made all the easier with a range of great-tasting flavours and easily-consumable formats”.

The CBD HEALTH® range includes such easy-to-consume formats as oral suspension gel, which gives outstanding absorption of water-soluble CBD via proprietary CBD HEALTH® liposomal technology. These gels come in the following flavours and added health benefits:

Heart: with Vitamin B1 to support a healthy heart, plus natural raspberry flavour

Immune: with added Vitamin C to support the immune system, plus natural lemon flavour

Physio: with Calcium to support normal muscle & bone function, plus natural blueberry flavour

Relax: with Lemon Balm to support relaxation and mental wellbeing

More can be found out about this range at https://canabidol.com/

About Canabidol®

Canabidol® is the cannabis company that brings unsurpassable provenance, compliance and transparency into the UK’s fledgling CBD industry.

As the UK’s leading experts in the field of consumers CBD products, we like to say “We know more. Simply because we do more”.

A family-owned company, founded in 2015 by our CEO, Tom Whettem, who also acts as a Director of the Cannabis Trades Association - the largest trade body of its type, globally representing 800 member companies and engaging with government departments.

From the very start we have challenged the status quo. While others invested in gimmicks, we invested in our company, our facilities our staff and most importantly our knowledge.

The only company nationally that exclusively owns and operates multiple sites covering the complete supply chain. Including a licenced cannabis farm, a dedicated extraction/purification facility, UK based manufacturing plant and a R&D facility.

With the concerns around the quality and legality of many CBD products on the market being Canabidol can provide the assurance and confidence where no other can. Verification on the safety, legality and conformity of Canabidol products is as simple as a quick search of the batch code found on every product that is produced.

Our passion for CBD and cannabis is our IP, our knowledge is our strength and our team is the driving force behind continuous innovation of our brands and products.

Brands & Products:

CANABIDOL® - The flagship range of Canabidol products developed to meet the exacting standards required in pharmacy sector. Quality is never an accident, It’s always the result of intelligent actions. The products within the range are a testament to passion for getting thing right, our dedication to excellence and our commitment to the highest standards at every stage.

The range includes CBD oils, Capsules, Sublingual Tablets, Vape Liquids and the UK’s first clinically-proven cannabis cosmetic.

CBD HEALTH® - Launched in 2019 following 2 years of development, the CBD Health range is the first of its kind to backed with approved EU Health Claims to substantiate their efficacy. Certified and permitted by the European Food Safety Authority.

The range includes Boost, Heart, Immune, Physio, Mind, Detox, Relax and Sleep that are highly targeted to meet the health specific health needs of the consumer

* For more information regarding media usage, ownership and rights please contact Stephen Batchelor.

Distributed by https://pressat.co.uk/ ]]>
09 Sep 2019 14:30:06 GMT
<![CDATA[ Fresh Award Win Highlights SmartSurvey’s Growing Presence in Global Online Survey Software Market ]]> https://pressat.co.uk/releases/fresh-award-win-highlights-smartsurveys-growing-presence-in-global-online-survey-software-market-bdf355fcdc0cc6c0e17713aa7fd61bb8 https://pressat.co.uk/releases/fresh-award-win-highlights-smartsurveys-growing-presence-in-global-online-survey-software-market-bdf355fcdc0cc6c0e17713aa7fd61bb8 Monday 9 September, 2019

Latest tech accolade caps a series of award wins during the Summer of 2019

Tewkesbury 9th
September 2019: Leading UK-based digital survey solutions provider, SmartSurvey, has been named a Rising Star in the Online Survey Software category of the Summer 2019 Customer Success Report, published by B2B software specialists Featured Customers. This latest accolade swiftly follows SmartSurvey’s award win with business technology software reviewers G2 Crowd, which is reflective of the online survey provider’s growing reputation and appeal in the global online survey software market.

Having launched in 2010, the rapidly growing online survey specialist, who is experiencing 40% year on year growth, has already become a trusted survey supplier to some of the world’s leading brands across multiple sectors.

SmartSurvey was one of only a few companies who successfully met the criteria necessary for inclusion in the survey software category of FeaturedCustomers’ Customer Success Report. The online survey provider earned their Rising Star award based on the authentication, quality and volume of their customer success content across a mix of case studies, testimonials and user reviews from multiple third-party sites.

Having seen how crucial research has become to the success of market leaders in both B2B and B2C sectors, companies of all sizes are now looking at how they can better utilise their data to make smarter decisions. They have realised the power that gathering internal and external feedback provides in helping them develop better strategies across marketing, training, employee relations, customer engagement and more; driving significant impact to their profitability and market share. Consequently, the demand for simple to use, quality survey software continues to grow. SmartSurvey’s ability to meet these requirements, together with the advanced performance and high levels of security offered by their survey software, has led to the company already successfully helping more than 250, 000 customers worldwide.

The latest awards are a great endorsement for the company and offers a marker towards their next stage of development, which SmartSurvey’s CEO, Mo Naser is extremely excited about:

“We are really delighted with this achievement, which together with our earlier award win with G2 Crowd, reflects our emergence as a significant player in the global online survey software market. Given today’s heightened customer concerns around data protection and security due to current Brexit uncertainties, our ability to provide clients with a completely UK based offering, both regards to our team and data, which is hosted on UK based servers, puts us at a distinct advantage. It is a value proposition, which very few of our rivals can offer. And it is an opportunity we are relishing, as we look forward to providing even more customers with the higher levels of data security assurances, they need to collect feedback throughout their business and drive better decisions and outcomes.”

More details about the Rising Star award, the Summer 2019 Customer Success Report and SmartSurvey’s profile, which includes detailed product scorecard ratings is available at: https://www.featuredcustomers.com/vendor/smartsurvey

Notes to editors

About SmartSurvey:

SmartSurvey is a UK-based provider of digital survey solutions. Launched in 2010, the company has rapidly grown into one of the leading online survey software suppliers in the UK and across Europe. Its powerful, secure and easy to use software, enables customers to create innovative surveys and questionnaires that helps them to deliver impactful results. A trusted provider for its customers, SmartSurvey is an ISO 27001 accredited and Cyber Essentials Plus Certified company, which hosts all its data securely on UK-based servers.

For more information go to: www.smartsurvey.co.uk

About FeaturedCustomers:

FeaturedCustomers, the world’s only customer reference platform for B2B business software & services, helps potential B2B buyers research and discover business software & services through vendor validated customer reference content such as customer testimonials, success stories, case studies, and customer videos. Every day their platform helps influence the purchasing decisions of thousands of B2B buyers in the final stages of their buying cycle from Fortune 500 companies to SMB’s.

For more information, visit their website.


For further information, please contact:

Phil Cleave

Content Marketing Executive


Email: phil@smartsurvey.co.uk

Tel: 01684 342267

* For more information regarding media usage, ownership and rights please contact SmartSurvey.

Distributed by https://pressat.co.uk/ ]]>
09 Sep 2019 13:06:33 GMT
<![CDATA[ Put prevention at a premium for place-based health dividend, Localis urges ]]> https://pressat.co.uk/releases/put-prevention-at-a-premium-for-place-based-health-dividend-localis-urges-0ac6ea6e7387d7d45389b220cf78acd3 https://pressat.co.uk/releases/put-prevention-at-a-premium-for-place-based-health-dividend-localis-urges-0ac6ea6e7387d7d45389b220cf78acd3 Friday 6 September, 2019

Ministers should fully fix cuts to public health funding and put a premium on preventative care budgets, targeting resources and funding to parts of the country that would benefit most from immediate help, a new report from the think-tank Localis has recommended.

In a report entitled ‘Local Practice – long-term sustainability through place-based health’, Localis calls for the introduction of a Prevention Premium – modelled after the schools’ Pupil Premium – to support the joined-up delivery of public health in an area.

The Prevention Premium would be calculated on population factors such as unemployment rate, numbers of children in low-income families and percentage over-65s as well as lifestyle factors such as smoking, childhood obesity and physical inactivity in adults.

According to analysis undertaken by Localis, residents of Blackpool, Hull and North East Lincolnshire are the top three areas that would benefit most from a prevention premium, followed by four North East areas including Middlesbrough, South Tyneside, Hartlepool and Sunderland.

The report also calls for major local employers to have a bigger role in improving community health alongside pleas for better use of NHS data and property assets.

To fix a looming crisis in the healthcare labour market, the report recommends local authorities should work hand-in-hand with NHS Trusts in filling gaps for overseas health and care workers after-Brexit, and also urges an overhaul to how we recruit and retain UK born nursing and social care staff in areas where they are most needed.

Report co-author, Localis research officer, Zayn Qureshi, said: “This report stresses the need for individuals to take back control over their own health and shows what could be possible by taking a whole-place view - one focused on delivering better health outcomes at local level.

“Where we live, and the communities in which we grow up in shape who we become, and this has a profound effect on our continual health. We must, therefore, help communities to constantly improve their collective health through a radical emphasis on the preventative as a first line of defence.”

“Localis chief executive, Jonathan Werran, said: “The Spending Round announcement of a real terms increase in the Public Health grant, helping local authorities continue to provide prevention and public health interventions is clearly a welcome step. But funding needs to be restored to 2015 levels as a minimum.

“Local Practice makes this funding case for a stronger place-based health system, offering a pragmatic argument for liberating resources, assets and the huge latent potential that exists within every community for generating greater wellbeing and prosperity.

“It is a call to rationally manage limited resources and deploy data and new technology for the best results. As such the report offers, we hope, a prescription to astutely integrate agents of health with guardians of place for the sake of delivering the best and most appropriate care to people through all stages of life.”

Report co-authors, Dr Geoffrey Boxer and Linda Boxer MBA, said: “Having worked across the spectrum of healthcare for almost 40 years we have first-hand experience of how the NHS operates, from primary care to management of services within a specialist teaching hospital environment through to research & development and clinical trials.

“We welcome this opportunity to use our unique perspective to consider what reforms might revolutionise the NHS and address the challenge of delivering increasingly complex and expensive therapies to an ageing population within a tightly constrained budget.

“Amongst the reforms that we believe have such potential is the encouragement of consumer-led healthcare and empowerment of local practitioners to generate solutions to specific regional healthcare and wellbeing issues.”


Press enquiries:

Jonathan Werran, chief executive, Localis
(Telephone) 0870 448 1530 / (Mobile) 07967 100328 / (Email) jonathan.werran@localis.org.uk

Notes to Editors:

A full copy of the report can be downloaded here:


The top ten places for preventative care demand are:

1 Blackpool

2 Kingston upon Hull, City of

3 North East Lincolnshire

4 Middlesbrough

5 South Tyneside

6 Hartlepool

7 Sunderland

8 Wolverhampton

9 Medway

10 Knowsley

Report recommendations:

1. We reiterate our call for local authorities to be given a coherent and comprehensive finance settlement that is fit for purpose. One that is set on longer cycles of ten years, which would facilitate long term planning of the prevention agenda.

2. In addition to the public health grant, upper tier local authorities should be provided with a Prevention Premium, modelled after the Pupil Premium grant for school funding, to help support the transition to public health delivery interlinked across all council functions and wider civil society actors and institutions. The premium would be calculated based on demographic factors, reflecting two pinch points for public health. On the one hand, the rate at which the population is ageing and on the other the prevalence of child poverty.

3. The new government should work toward releasing the Social Care Funding Green Paper at the earliest convenience, the paper should contain guidance on the joining-up of services to create holistic public health strategies as a form of preventative care.

4. The beneficial role Local Economic Anchors can play in tackling emerging public health challenges should be recognised by giving them a seat at the table on Health and Wellbeing Boards. This would lead to further collaboration between all local stakeholders including the local health and social care sector, local authorities and business.

5. Integrated Care Systems should be funded to employ health economists, to evaluate public health initiatives within a place and their effect on local NHS demand.

6. Roles should be created within Integrated Care Systems for marketing specialists, to work with local authorities within the ICS area to develop links between the NHS, the local community and the commercial healthcare and fitness sectors.

7. Constituent local authorities should be given a formalised role to act as conveners for Integrated Care Systems to actively engage with local educational institutions, to ensure a holistic, joined-up health education system, sensitive to local context, is in place.

8. CCG mergers should be halted and rolled back, with the aim of achieving parity with local government to ensure the legitimacy of locally-delivered healthcare.

9. Government, the NHS and local authorities must commit to greater collaborative working. Central to this, these partners must also sensitively and securely unlock greater potential from locally-derived patient data ‘the jewel in the health service crown’. This will mean funding to build robust systems for the effective storing, mining and analysis of larger databases including clinical and public health outcomes at appropriate sub-regional level. From this point forward, joint funding arrangements involving NHS England should be put in place, with the goal of analysing the success of health interventions across local public services.

10. In line with existing reforms to public property assets, efforts should be made by managers of the NHS estate to collocate different healthcare professionals from across the health service – e.g. GPs, nurses, pharmacists – in modern working environments within the community that support best patient care.

11. A joint nursing role that combines health and social care responsibilities should be created. This would accelerate steps toward delivering integrated care, give nurses a practical understanding of what this means, and offer concrete career prospects. For example, by employing individuals on a rotational basis whereby they work part time in the community, and part time in the acute setting, one would develop a range of skill sets, which would allow people more scope and opportunity regarding their career prospects.

12. A comprehensive immigration system that puts place-based needs first is essential post-Brexit. We propose a deal whereby visa quotas per sector are devolved to local government as they are best suited to know the needs for growth in their area. Local authorities in partnership with local NHS trusts are in a better position to identify their and recruit for themselves. Even outside of healthcare, local authorities can identify key sectors where immigration is needed and can fill gaps whilst creating incentives for people to take opportunities to train and work in their areas.

13. Efforts should be doubled to reverse the fall in numbers of nurses, GPs, and other health and social care professionals through a focus on increased homebased training. A start should be reversing the abolition of bursaries for nursing students. More institutions and places to study should be made available, with clear incentives laid out for training in specialities where there are current shortages. This should involve having clearly laid out opportunities for an upward career trajectory to boost morale.

14. Efforts should also be made to attract more young British people to work in social care, especially in areas which have experienced a brain drain and thus have a higher median age. This involves a necessary boost of investment into the social care budget, which would allow for raising wages, and creating new opportunities and prospects for social workers.

About Localis

Who we are

We are an independent, cross-party, leading not-for-profit think tank that was established in 2001. Our work promotes neo-localist ideas through research, events and commentary, covering a range of local and national domestic policy issues.


Our research and policy programme is guided by the concept of neo-localism. Neo-localism is about giving places and people more control over the effects of globalisation. It is positive about promoting economic prosperity, but also enhancing other aspects of people’s lives such as family and culture. It is not anti-globalisation, but wants to bend the mainstream of social and economic policy so that place is put at the centre of political thinking.

In particular our work is focused on the following areas:

• Reshaping our economy. How places can take control of their economies and drive local growth.

• Culture, tradition and beauty. Crafting policy to help our heritage, physical environment and cultural life continue to enrich our lives.

• Reforming public services. Ideas to help save the public services and institutions upon which many in society depend.

What we do

We publish research throughout the year, from extensive reports to shorter pamphlets, on a diverse range of policy areas.

We run a broad events programme, including roundtable discussions, panel events and an extensive party conference programme.

We also run a membership network of local authorities and corporate fellows.


* For more information regarding media usage, ownership and rights please contact Localis.

Distributed by https://pressat.co.uk/ ]]>
06 Sep 2019 06:00:02 GMT
<![CDATA[ On-Demand Doctors, Nurses Healthcare Services App Courting Investors ]]> https://pressat.co.uk/releases/on-demand-doctors-nurses-healthcare-services-app-courting-investors-129637cf9c26e17a2283ac2e5ed2004c https://pressat.co.uk/releases/on-demand-doctors-nurses-healthcare-services-app-courting-investors-129637cf9c26e17a2283ac2e5ed2004c Tuesday 3 September, 2019

Scruubs, an app that
will provide "Uber-like" on-demand, non-emergency health
and wellness services by doctors, nurses and other professionals, has
opened their startup round to global investors.

Atlanta, GA USA. Over
three hundred licensed medical and non-medical professionals have
signed up to begin taking house calls for Scruubs when it launches in
October. Doctors, nurses, lab technicians and others can be requested
to homes or offices to perform routine care, examinations and
clinical tests. Other available services include cleaning orderlies
and medical transportation drivers. Scruubs began taking applications
for the medical positions in July and surpassed their goal in two
weeks. The healthcare disruptor app has now opened a startup round
for accredited investors and potential business partners.

"We expected a huge
interest from medical professionals, but not as many applicants as we
received," says Lisa Lamb, Scruubs founder and chief operations
officer. "We are limiting the onboarding amount to two hundred
for the launch, and adding more as demand grows. There are several
primary care doctors in the major counties that want to participate
and we are really happy with the early support we've received."

Scruubs does not require
or accept health insurance. The amount per Scruubs visit by a
licensed medical professional is from $50 - $100USD, and medical
rides start at $1.50USD per mile. Users will be able to use a major
credit, debit card, third party payment services or cryptocurrency to pay for their visits and medical rides.

"Our goals are to
reach the unemployed and the uninsured in the midst of the healthcare
crisis," says Lamb. "We also wanted to add multiple, new
era payment options to make us attractive to millennials. Healthcare
shouldn't be limited to monthly premium debits from bank accounts."

Scruubs will provide
additional income to medical professionals who would prefer not to
work in hospitals or clinics. Scruubs professionals are not
employees, but trained, licensed, insured independent contractors.
Scruubs requires proof of license to practice, background checks and
drug screening of all professionals before they will be allowed to
use the application. Scruubs is the brainchild of a private
practicing nurses aide that has programmed the application to operate
similar to the popular ride-sharing model.

"I hated working in
hospitals and nursing homes under strict schedules and administrative
rules. Scruubs will allow doctors and nurses to provide care on their
own terms, and in the patient's best interests."

Scruubs has opened its
startup round to accredited investors and partners directly from its
official website, and the founder will address accredited investors
and potential partners in a pitch webinar on 506er.com later this

"We definitely want
to grow and make health and wellness services accessible without
having insurance," says Lamb. "Getting the right investors
and partners on board early will help us with our mission. We want
Scruubs to be an international brand."

About 506er.com

506er.com is an investor
and crowdfunding pitch site. For more information about Scruubs'
upcoming pitch, https://506er.com

About Scruubs

Scruubs is a Georgia-based
U.S. Corporation that will provide non-emergency healthcare and wellness
services via mobile application. Accredited investors may purchase
shares directly from https://scruubs.com

Official website:

Contact Scruubs

Lisa Lamb, MA, CNA, PCT.   

CEO/COO Scruubs


PH: 1-678-258-5860


Other: <iframe width="560" height="315" src="https://www.youtube.com/embed/WstxNHFa34k" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
Other: <iframe width="560" height="315" src="https://www.youtube.com/embed/dA7e8poXNnU" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
Other: <iframe width="560" height="315" src="https://www.youtube.com/embed/8RXoX_qVs0Q" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
Other: <iframe width="560" height="315" src="https://www.youtube.com/embed/Iet8mkNzgIc" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
* For more information regarding media usage, ownership and rights please contact Scruubs.

Distributed by https://pressat.co.uk/ ]]>
03 Sep 2019 09:28:51 GMT
<![CDATA[ International consensus on testosterone treatment for women. ]]> https://pressat.co.uk/releases/international-consensus-on-testosterone-treatment-for-women-3d27b84a107162891909395184cc9bbd https://pressat.co.uk/releases/international-consensus-on-testosterone-treatment-for-women-3d27b84a107162891909395184cc9bbd Monday 2 September, 2019

Agreement among leading experts about the benefits and risks of testosterone therapy for postmenopausal women.

EMBARGO: 00.01 BST 2 September 2019

The first Global Position Statement on the use of testosterone in the treatment of women, led by the International Menopause Society (IMS), was published in four leading international medical journals today. The statement has been authored by a diverse team of leading experts based around the world and has been endorsed by internationally-esteemed medical societies.

It follows years of debate regarding testosterone therapy for women and, for the first time, provides agreement among experts and medical societies about how testosterone could be prescribed for women.

An international task force of experts from leading medical societies, brought together by the IMS, produced the Global Position Statement to provide clear guidance regarding the prescribing and measurement of testosterone for female testosterone therapy as well as advice on testosterone prescribing practices that have the potential to be ineffectual or cause harm.

They concluded that testosterone can be effective at improving sexual wellbeing for postmenopausal women with Hypoactive Sexual Desire Dysfunction (HSDD). Recognised benefits included improved sexual desire, arousal, orgasm and pleasure, together with reduced concerns and distress about sex.

HSDD is thought to affect around 32% of women at midlife; and, while it's common for women to lose interest in sex around the time of the menopause and after, the use of testosterone as a treatment offers women an approach that may significantly improve their sexual and related emotional wellbeing.

Professor Susan Davis, President of the International Menopause Society said:

“This position statement has far reaching global consequences. It not only reassures clinicians that a trial of testosterone therapy is appropriate for women with HSDD, but very emphatically states that, at present, the available evidence does not support the use of testosterone for any other symptoms or medical condition.

“It also clearly advises that when testosterone therapy is given, the resultant blood levels should not be above those seen in healthy young women. We hope this will allow women who may benefit to be offered treatment, and simultaneously protect women from receiving inappropriate testosterone therapy.

“I am very proud that the IMS has led on the development of this crucial medical guidance”.

Dr. Sharon Parish, Professor of Clinical Medicine and Professor of Medicine in Clinical Psychiatry at Weill Cornell Medical College added:

“The Global Position Statement has been developed, approved, and endorsed by a broad group of experts from international women's health, sexual medicine, endocrine, gynecological and menopause societies across the world.

“The key messages for clinicians and researchers who care for and study postmenopausal women across a wide array of clinical and research disciplines are that testosterone clearly has positive benefits on sexual function and minimal side effects and low risk profiles, and is a very important and critical treatment option for postmenopausal women with HSDD.”

The international panel is calling on industry, researchers, and funding organisations to recognise the need for further research into testosterone therapy for women of all ages and the development and licensing of products formulated specifically for women.

The statement was developed by a multinational, multidisciplinary task force, the members of which were delegates from leading medical societies, and was peer reviewed by expert committees of endorsing societies from across the world. It has been translated into 13 languages and aims to improve the sexual wellbeing of women on a global scale.


Notes to editors:

For further information contact Louise Akers: louise.akers@campaigncollective.org +44 7712273928

About the International Menopause Society

A Charitable Incorporated Organisation based in the UK, The International

Menopause Society (IMS) brings together the world’s leading experts to

collaboratively study and share knowledge about all aspects of aging in women.

The IMS advocates evidence-based treatment options that optimise mid-life

women’s health and promotes best practice in women’s health care to healthcare

professionals and women across the globe.

IMS activities include:

building communities of practice through its membership and Council of

Affiliated Societies;

publishing original research, reviews, statements and recommendations;holding events to disseminate information including the bi-annual World

Congress on Menopause, symposia and workshops

offering online practitioner training resourcesthe annual World Menopause Day awareness raising campaign

About the Global Position Statement on testosterone treatment for women

The Global Position Statement was developed to inform health care professionals of the known benefits and potential risks of testosterone therapy for women. The aims were to provide clear guidance as to which women might benefit from testosterone therapy; identify symptoms, signs, and conditions for which evidence does not support the prescribing of testosterone; explore areas of uncertainty; and to identify any prescribing practices that have the potential to cause harm.

The panel concluded that:

a testosterone blood level should not be used to diagnose HSDD. HSDD should be diagnosed following a careful medical assessment that elicits lowered sexual desire with associated personal distress and no other treatable cause. Read more here. there is only evidence for beneficial effects of testosterone therapy in postmenopausal women, and specifically those suffering with HSDD there is insufficient data to support the use of testosterone for the treatment of any other symptom or clinical condition or for disease preventiontestosterone treatment should only be with formulations that achieve blood concentrations of testosterone that approximate what is normal for premenopausal womenalthough treatment of postmenopausal women with doses that result in blood levels seen in premenopausal women was associated with mild increases in acne and body/facial hair in some women, it was not associated with scalp hair loss or voice changeas no approved testosterone for women is presently approved by any national regulatory body, male formulations can be used judiciously in small doses with blood testosterone concentrations monitored regularly compounded testosterone should not be used if a regulatory approved product is availablelarger studies are needed to inform clinical recommendations regarding the use of testosterone for HSDD in premenopausal womenstudies must be undertaken to establish the longer-term cardiometabolic and breast safety of testosterone therapy for women.

The advice was developed by nine leading medical organisations including The International Menopause Society, The International Society for Sexual Medicine, The Federacion Latinoamericana de Sociedades de Climaterio y Menopausia, The American College of Obstetricians and Gynecologists, The North American Menopause Society, The European Menopause and Andropause Society, The International Society for the Study of Women’s Sexual Health, The Royal College of Obstetricians and Gynaecologists, and The Endocrine Society, and endorsed by several additional Societies.It was published on 2 September 2019 in four leading international medical journals: Climacteric, Maturitas, The Journal of Sexual Medicine, and The Journal of Clinical Endocrinology and Metabolism.The Global Position Statement is based on the world wide published literature in this field, including a recent systematic review and meta-analysis of clinical trials of testosterone therapy in women published in the Lancet Diabetes and Endocrinology on 25th July 2019, and where data were not available, on expert opinion of international leaders in this field.There are no clearly established indications for testosterone therapy for women prior to the publication of the consensus statement.There was no external funding for this process which was entirely supported by grants from the participating societies.Translated versions of the Global Position Statement are available on the International Menopause Society website: https://www.imsociety.org/position_papers_and_consensus_statements.php you can also view the statement here.Visit www.imsociety.org to find out more.

https://drive.google.com/file/d/0B2vLlNxJ-oWNT2dEU3FfODd1aFZRZlY4LVY5N3pJMEtaU18w/view https://www.imsociety.org/position_papers_and_consensus_statements.php
* For more information regarding media usage, ownership and rights please contact Campaign Collective.

Distributed by https://pressat.co.uk/ ]]>
02 Sep 2019 08:05:02 GMT
<![CDATA[ Spotlight on John Weiss & Son trusted brand; FEATHER scalpels, blades & holders ]]> https://pressat.co.uk/releases/spotlight-on-john-weiss-son-trusted-brand-feather-scalpels-blades-holders-6da27384bc7da69ae056e1dd48f6d14d https://pressat.co.uk/releases/spotlight-on-john-weiss-son-trusted-brand-feather-scalpels-blades-holders-6da27384bc7da69ae056e1dd48f6d14d Friday 23 August, 2019

Harlow, UK – 23rd August 2019 - John Weiss & Son, the leading manufacturer and distributor of gold-standard ophthalmic micro-surgical instruments and procedures, is proud to be the Authorised UK Distributor for the World-class FEATHER
range of ophthalmic scalpels, blades and holders.

FEATHER is a global market leader in the manufacture of high-quality surgical cutting instruments. The range includes; the FEATHER standard range of surgical instruments, a diverse ophthalmic MICRO FEATHER range and a portfolio of highly-specialised microsurgical instruments.

The FEATHER Standard Range of surgical instruments includes; disposable scalpels, safety scalpels, surgical blades & handles and blade removers. Due to their optimised micrometre-accurate precision grinding, FEATHER standard surgical scalpels offer outstanding quality and performance. The double-honing process ensures ultra-sharp cutting edges of superb durability.

The FEATHER ophthalmic MICRO FEATHER range is the most diverse available. It includes; sideports, phaco & enlargement incisions, tunnel incisions & preparation of flaps and incisions with pre-defined incision depth scalpels. Blade handles can be aluminium, plastic or Safeshield handles, with a blade type of either straight or angled. Due to the quality of the stainless steel and the exceptional manufacturing process, these provide ultimate cutting consistency and sharpness.

Constituting an ideal system of inter-changeable blades and handles, FEATHER Microsurgical Instruments are flexible and efficient. They are easy-to-handle, very durable and have ultra-sharp cutting edges, reducing the risk of tissue injury during incision. The handles are made from titanium alloy and have an ideal weight to ensure a secure grip and safe handling of the instruments.

Unique in design, the Microsurgical instrument portfolio offers highly-specialised solutions for neurosurgeons, including blades designed for cutting Dura Mater and Arachnoid Membrane, in addition to other brain tissues.

For more information on FEATHER blades, please visit https://jweiss.co/feather
or call 01279 883858.

* For more information regarding media usage, ownership and rights please contact John Weiss & Son.

Distributed by https://pressat.co.uk/ ]]>
23 Aug 2019 11:02:12 GMT